恒瑞医药：药物注射用SHR-1826纳入突破性治疗品种名单

Core Viewpoint - Heng Rui Medicine's subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has had its injectable SHR-1826 included in the list of breakthrough therapies by the National Medical Products Administration (NMPA) [1] Group 1: Product Development - SHR-1826 is intended for the treatment of locally advanced or metastatic non-squamous non-small cell lung cancer that is c-Met overexpressing (2-3+, ≥50%) and has failed at least one line of systemic therapy [1]